Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03088176 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | unknown | Phase 1 | 4 | West Cancer CenterOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03086174 | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma | unknown | Phase 1 | 24 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04021420 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma(SONIMEL01) | unknown | Phase 1 / Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04072900 | A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma | unknown | Phase 1 | 30 | Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04357509 | The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma | unknown | Phase 1 | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04206358 | Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma | unknown | Phase 1 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma(ENIgMA) | unknown | Phase 1 | 21 | Markus JoergerOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02759536 | In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma | unknown | Phase 1 / Phase 2 | 30 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT02202200 | Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma(OPTIMUM) | unknown | Phase 1 / Phase 2 | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02671513 | A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | unknown | Phase 1 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 12, 2016 | clinicaltrials |
| NCT02619058 | A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients | unknown | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients(NIBIT-M4) | unknown | Phase 1 | 19 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01882946 | Safety and Efficacy Study of DCVax-Direct in Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Northwest BiotherapeuticsINDUSTRY | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00002817 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00538005 | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | unknown | Phase 1 / Phase 2 | 54 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00004025 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00010309 | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00022568 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 1 | — | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00037037 | Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma | unknown | Phase 1 | — | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00391300 | Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions | unknown | Phase 1 | 100 | Eastern Virginia Medical SchoolOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00003747 | Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma | unknown | Phase 1 | 30 | Mount Vernon Cancer Centre at Mount Vernon HospitalOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00016055 | Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma | unknown | Phase 1 | 18 | St. Luke's Medical CenterOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00002781 | Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma | unknown | Phase 1 | 15 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00006035 | Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00017355 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 1 | — | Baylor Health Care SystemOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00126685 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 30 | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum ErlangenOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT01082198 | Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes | unknown | Phase 1 / Phase 2 | 22 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01331915 | Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients(THERAVAC) | unknown | Phase 1 / Phase 2 | 23 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT01614301 | Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 136 | University of RegensburgOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT01584115 | Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) | unknown | Phase 1 / Phase 2 | 15 | Instituto de Investigação em ImunologiaOTHER | 1 | Apr 25, 2012 | clinicaltrials |
| NCT00409383 | Abraxane and Temodar Plus Genasense in Advanced Melanoma | unknown | Phase 1 | 28 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00811759 | Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00701987 | Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma | unknown | Phase 1 | 12 | Advanced Life Sciences, Inc.INDUSTRY | 1 | Feb 3, 2010 | clinicaltrials |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | unknown | Phase 1 / Phase 2 | 70 | Julius-Maximilians UniversityOTHER | 1 | Jul 28, 2006 | clinicaltrials |
| NCT00111046 | Pain Relief - Tramadol Versus Ibuprofen | unknown | Phase 1 / Phase 2 | 40 | Royal Liverpool University HospitalOTHER_GOV | 1 | Nov 10, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 12, 2020source: clinicaltrials